Intensive care medicine

Bedaquiline

Staphylococcus aureus

Bacteria

Biology

Mycobacterium tuberculosis

Drug resistance

Extensively drug-resistant tuberculosis

Linezolid

Drug

Isoniazid

Genetics

Microbiology

Tuberculosis

Internal medicine

Pharmacology

Epidemiology

Rifampicin

Medicine

Vancomycin

GeneXpert MTB/RIF

Pathology

International Journal of Infectious Diseases

AimThe aim of this review is to inform the reader on the latest developments in epidemiology, diagnostics and management.EpidemiologyDrug-resistant Tuberculosis (DR-TB) continues to be a current global health threat, and is defined by higher morbidity and mortality, sequelae, higher cost and complexity. The WHO classifies drug-resistant TB into 5 categories: isoniazid-resistant TB, rifampicin resistant (RR)-TB and MDR-TB, (TB resistant to isoniazid and rifampicin), pre-extensively drug-resistant TB (pre-XDR-TB) which is MDR-TB with resistance to a fluoroquinolone and finally XDR-TB that is TB resistant to rifampicin, plus any fluoroquinolone, plus at least one further priority A drug (bedaquiline or linezolid). Of 500,000 estimated new cases of RR-TB in 2020, only 157 903 cases are notified. Only about a third of cases are detected and treated annually.DiagnosticsRecently newer rapid diagnostic methods like the GeneXpert, whole genome sequencing and Myc-TB offer solutions for rapid detection of resistance.TreatmentThe availability of new TB drugs and shorter treatment regimens have been recommended for the management of DR-TB.ConclusionDespite advances in diagnostics and treatments we still have to find and treat two thirds of the drug resistant cases that go undetected and therefore go untreated each year. Control of TB and elimination will only occur if cases are detected, diagnosed and treated promptly.

Drug resistant TB – latest developments in epidemiology, diagnostics and management